{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T04:25:13Z","timestamp":1769574313555,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12969-015-0054-4","type":"journal-article","created":{"date-parts":[[2015,12,3]],"date-time":"2015-12-03T06:58:42Z","timestamp":1449125922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Tuberculosis in pediatric patients treated with anti-TNF\u03b1 drugs: a cohort study"],"prefix":"10.1186","volume":"13","author":[{"name":"Carmen Garc\u00eda de Vicu\u00f1a Mu\u00f1oz de la Nava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Calzada-Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Anton-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Bou-Torrent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Est\u00edbaliz","family":"Iglesias-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00edlvia","family":"Ricart-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Mart\u00edn de Carpi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicen\u00e7","family":"Torrente-Segarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"S\u00e1nchez-Manubens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Gim\u00e9nez-Roca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Librada","family":"Rozas-Quesada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Juncosa-Morros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e0udia","family":"Fortuny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Noguera-Julian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,12,3]]},"reference":[{"key":"54_CR1","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","volume":"60","author":"F Tubach","year":"2009","unstructured":"Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Br\u00e9ban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60:1884\u201394.","journal-title":"Arthritis Rheum"},{"key":"54_CR2","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","volume":"60","author":"LP Ormerod","year":"2005","unstructured":"Ormerod LP, Milburn HJ, Gillespie S, Ledingham J, Rampton D. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax. 2005;60:800\u20135.","journal-title":"Thorax"},{"key":"54_CR3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/421494","volume":"39","author":"AK Mohan","year":"2004","unstructured":"Mohan AK, Cot\u00e9 TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis. 2004;39:295\u20139.","journal-title":"Clin Infect Dis"},{"key":"54_CR4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/INF.0b013e3182833cbb","volume":"32","author":"A Woerner","year":"2013","unstructured":"Woerner A, Ritz N. Infections in children treated with biological agents. Pediatr Infect Dis J. 2013;32:284\u20138.","journal-title":"Pediatr Infect Dis J"},{"key":"54_CR5","doi-asserted-by":"crossref","unstructured":"Moreno-P\u00e9rez D, Andr\u00e9s Mart\u00edn A, Altet G\u00f3mez N, Baquero-Artigao F, Escribano Montaner A, G\u00f3mez-Pastrana Dur\u00e1n D, et al. Diagnosis of tuberculosis in pediatrics. Consensus document of the Spanish Society of Pediatric Infectology (SEIP) and the Spanish Society of Pediatric Pneumology (SENP). An Pediatr (Barc). 2010. doi: 10.1016\/j.anpedi.2009.12.017 .","DOI":"10.1016\/j.anpedi.2009.12.017"},{"key":"54_CR6","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/cid\/cit489","volume":"57","author":"SS Toussi","year":"2013","unstructured":"Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-\u03b1 inhibitors: systematic review of the literature. Clin Infect Dis. 2013;57:1318\u201330.","journal-title":"Clin Infect Dis"},{"key":"54_CR7","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56:3096\u2013106.","journal-title":"Arthritis Rheum"},{"key":"54_CR8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/rheumatology\/keh074","volume":"43","author":"W Armbrust","year":"2004","unstructured":"Armbrust W, Kamphuis SS, Wolfs TW, Fiselier TJ, Nikkels PG, Kuis W, et al. Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2004;43:527\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"54_CR9","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJMoa011858","volume":"346","author":"A Myers","year":"2002","unstructured":"Myers A, Clark J, Foster H. Tuberculosis and treatment with infliximab. N Engl J Med. 2002;346:623\u20136.","journal-title":"N Engl J Med"},{"key":"54_CR10","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00431-011-1501-y","volume":"170","author":"S Hess","year":"2011","unstructured":"Hess S, Hospach T, Nossal R, Dannecker G, Magdorf K, Uhlemann F. Life-threatening disseminated tuberculosis as a complication of TNF-\u03b1 blockade in an adolescent. Eur J Pediatr. 2011;170:1337\u201342.","journal-title":"Eur J Pediatr"},{"key":"54_CR11","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3899\/jrheum.100058","volume":"37","author":"P Kharbanda","year":"2010","unstructured":"Kharbanda P, Dagaonkar R, Balakrishnan C, Udwadia ZF. Tumor necrosis factor-alpha blocker induced tuberculosis. J Rheumatol. 2010;37:1542.","journal-title":"J Rheumatol"},{"key":"54_CR12","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/INF.0000000000000286","volume":"33","author":"AT Cruz","year":"2014","unstructured":"Cruz AT, Karam LB, Orth RC, Starke JR. Disseminated tuberculosis in two children with inflammatory bowel disease receiving infliximab. Pediatr Infect Dis J. 2014;33:779\u201381.","journal-title":"Pediatr Infect Dis J"},{"key":"54_CR13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/MPG.0b013e31822938c3","volume":"54","author":"N Jordan","year":"2012","unstructured":"Jordan N, Waghmare A, Abi-Ghanem AS, Moon A, Salvatore CM. Systemic mycobacterium avium complex infection during antitumor necrosis factor-a therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2012;54:294\u20136.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"54_CR14","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.crohns.2010.05.001","volume":"4","author":"K Cheent","year":"2010","unstructured":"Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn\u2019s disease. J Crohns Colitis. 2010;4:603\u20135.","journal-title":"J Crohns Colitis"},{"key":"54_CR15","first-page":"9","volume":"6","author":"AM Sacrist\u00e1n","year":"2004","unstructured":"Sacrist\u00e1n AM, Casares I, Lage MJ. Prevalencia de infecci\u00f3n tuberculosa en adolescentes de 11 a 14 a\u00f1os en Palencia. Rev Pediatr Aten Primaria. 2004;6:9\u201317.","journal-title":"Rev Pediatr Aten Primaria"},{"key":"54_CR16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10067-009-1334-5","volume":"29","author":"NA Ayaz","year":"2010","unstructured":"Ayaz NA, Demirkaya E, Bilginer Y, Oz\u00e7elik U, Cobano\u011flu N, Kiper N, et al. Preventing tuberculosis in children receiving anti-TNF\u03b1 treatment. Clin Rheumatol. 2010;29:389\u201392.","journal-title":"Clin Rheumatol"},{"key":"54_CR17","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00296-009-1170-6","volume":"30","author":"T Cagatay","year":"2010","unstructured":"Cagatay T, Aydin M, Sunmez S, Cagatay P, Gulbaran Z, Gul A, et al. Follow-up results of 702 patients receiving tumor necrosis factor-\u03b1 antagonists and evaluation of risk of tuberculosis. Rheumatol Int. 2010;30:1459\u201363.","journal-title":"Rheumatol Int"},{"key":"54_CR18","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1007\/s00296-011-2030-8","volume":"32","author":"O Kilic","year":"2012","unstructured":"Kilic O, Kasapcopur O, Camcioglu Y, Cokugras H, Arisoy N, Akcakaya N. Is it safe to use anti-TNF-\u03b1 agents for tuberculosis in children suffering with chronic rheumatic disease? Rheumatol Int. 2012;32:2675\u20139.","journal-title":"Rheumatol Int"},{"key":"54_CR19","doi-asserted-by":"crossref","unstructured":"Maritsi D, Al-Obadi M, Brogan PA, Eleftheriou D, Dixon GL. The performance of Quantiferon TB Gold in-Tube as a screening tool in paediatric rheumatology prior to initiation of infliximab: a single centre\u2019s experience. ISRN Rheumatol. 2011. doi: 10.5402\/2011\/505171 .","DOI":"10.5402\/2011\/505171"},{"key":"54_CR20","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1136\/annrheumdis-2011-200408","volume":"71","author":"X Mariette","year":"2012","unstructured":"Mariette X, Baron G, Tubach F, Liot\u00e9 F, Combe B, Miceli-Richard C, et al. Influence of replacing tuberculin skin test with ex vivo interferon \u03b3 release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF\u03b1 therapy. Ann Rheum Dis. 2012;71:1783\u201390.","journal-title":"Ann Rheum Dis"},{"key":"54_CR21","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1136\/annrheumdis-2011-200941","volume":"71","author":"S Kleinert","year":"2012","unstructured":"Kleinert S, Tony HP, Krueger K, Detert J, Mielke F, Rockwitz K, et al. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-\u03b3 release assays under real-life conditions. Ann Rheum Dis. 2012;71:1791\u20135.","journal-title":"Ann Rheum Dis"},{"key":"54_CR22","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1136\/annrheumdis-2012-201979","volume":"71","author":"KL Winthrop","year":"2012","unstructured":"Winthrop KL, Weinblatt ME, Daley CL. You can\u2019t always get what you want, but if you try sometimes (with two tests--TST and IGRA--for tuberculosis) you get what you need. Ann Rheum Dis. 2012;71:1757\u201360.","journal-title":"Ann Rheum Dis"},{"key":"54_CR23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/MPG.0000000000000205","volume":"58","author":"O Hradsky","year":"2014","unstructured":"Hradsky O, Ohem J, Zarubova K, Mitrova K, Durilova M, Kotalova R, et al. Disease activity is an important factor for indeterminate interferon-\u03b3 release assay results in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2014;58:320\u20134.","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-015-0054-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T20:57:29Z","timestamp":1498251449000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ped-rheum.com\/content\/13\/1\/54"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["54"],"URL":"https:\/\/doi.org\/10.1186\/s12969-015-0054-4","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"article-number":"54"}}